A small pharmaceutical company in Chapel Hill has landed a $15 million raise to advance multiple clinical programs focused on pulmonary diseases.
The funding will support Renovion as it moves forward three different programs, including a phase 3 study that recently began enrolling patients as well as two phase 2 studies — one of which began in 2022 and another that will kick off his year. The raise gives the company a 24-month runway to see it through the studies.
The raise was driven by individuals…
